Yolk Sac Tumor Clinical Trials

6 recruiting

Yolk Sac Tumor Trials at a Glance

8 actively recruiting trials for yolk sac tumor are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Houston, Pittsburgh, and Nashville. Lead sponsors running yolk sac tumor studies include Children's Oncology Group, Baylor College of Medicine, and BeOne Medicines.

Browse yolk sac tumor trials by phase

Treatments under study

About Yolk Sac Tumor Clinical Trials

Looking for clinical trials for Yolk Sac Tumor? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Yolk Sac Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Yolk Sac Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric Cancer+2 more
BeOne Medicines140 enrolled20 locationsNCT06427941
Recruiting
Phase 2

Agnostic Therapy in Rare Solid Tumors

Cancer of Unknown PrimarySoft Tissue SarcomaCholangiocarcinoma+38 more
Instituto do Cancer do Estado de São Paulo28 enrolled8 locationsNCT06638931
Recruiting
Phase 3

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Germ Cell TumorChildhood Extracranial Germ Cell TumorExtragonadal Embryonal Carcinoma+27 more
Children's Oncology Group1,780 enrolled630 locationsNCT03067181
Recruiting
Phase 1

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Liver CancerRhabdomyosarcomaWilms Tumor+3 more
Baylor College of Medicine24 enrolled1 locationNCT04715191
Recruiting
Phase 2

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Central Nervous System Nongerminomatous Germ Cell TumorChoriocarcinomaEmbryonal Carcinoma+7 more
Children's Oncology Group160 enrolled165 locationsNCT04684368
Recruiting
Phase 1

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

Hepatocellular CarcinomaRhabdomyosarcomaWilms Tumor+7 more
Seattle Children's Hospital21 enrolled1 locationNCT07148050
Recruiting
Phase 1

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Hepatocellular CarcinomaRhabdomyosarcomaWilms Tumor+5 more
Baylor College of Medicine21 enrolled1 locationNCT06198296
Recruiting

Molecular Epidemiology of Pediatric Germ Cell Tumors

GerminomaGerm Cell TumorTeratoma+6 more
Children's Oncology Group1,151 enrolled1 locationNCT05564026